**Covering letter**

The Scientific Committee,

Second IAMRS Conference.

Submission of Abstract for the Conference

Dear Sirs,

We intend to present the attached article entitled **“ Role of Nuclear Medicine in the Management of Thyroid Cancer ”** in your Second IAMRS Conference. On behalf of all contributors, I will act as the corresponding author from this point onward. We have no conflict of interest in any substance or material mentioned in this manuscript.

Yours sincerely,

Corresponding Author: RAFID RIYADH AL-TUMA

Affiliation: Iraqi Ministry of Health, Basra Health Directorate

Email: rafidforever@yahoo.com

Mobile: +964 7811710024

Contributing Authors Affiliation Email Mobile

1.

2.

3.

4.

**Abstract**

Thyroid cancer is one of the most common malignant tumors in the endocrine system. It is classified into differentiated thyroid cancer (DTC), medullary, and anaplastic types.

Molecular imaging plays an important role in diagnosing and treating thyroid cancer, because it allows visual representation, characterization, and quantification of the biological characteristics of cells and tissues in the patients and also helps ensure that patients get the optimal medical therapy for their disease or personalized treatment.

Of all the molecular imaging methods, molecular nuclear medicine has made advances rapidly in both diagnosis and treatment of thyroid cancer. Molecular nuclear imaging especially can semiquantitatively or quantitatively demonstrate the alterations in specific molecules of thyroid cancer on cellular and molecular level. Moreover, multimodal nuclear imaging is essential to design the lesion-based multimodal treatment strategy for patients with multiple heterogeneous metastatic lesions